Sydney, Australia – April 12, 2024 - At Omico, we are building and supporting a network of clinical trial sites to provide the latest treatment options to cancer patients. TheOmico National Clinical Trials Network (ONCTN), coordinated by Lucille Sebastian, is working towards offering more treatment options to patients and ensuring equitable access to clinical trials. Omico is collaborating with stakeholders including clinical trial units, clinicians, patients, and pharmaceutical companies.

Sydney, Australia – March 12, 2024 – Omico, the pioneering, not-for-profit, national organisation accelerating access to precision oncology in Australia, proudly announces Ian Black as its new full-time Chief Executive Officer (CEO), effective 2 April 2024. Mr Black joins Professor David Thomas, Omico’s founder, who will continue to play a vital role within the organisation. This transition signifies a pivotal moment in Omico's journey, a necessary evolution of its organisational structure to effectively manage current priorities, ongoing growth and ensure longterm sustainability.

Pioneering national genomics initiative gives 23,000 Australians their best fighting chance against the toughest cancers

As of March 2023, we have screened more than 7,000 patients through our Molecular Screening & Therapeutics (MoST) study.

Research led by Omico, the Garvan Institute of Medical Research and UNSW Sydney has generated the first comprehensive genetic map of sarcomas, identifying several new important genes that when inherited can cause this deadly cancer. The research has wide implications for people living with sarcoma and their families – allowing detection of the cancer earlier and potentially improving survival for patients.

The Australian Government’s Federal Budget announcement brings new hope to Australian families carrying gene variants with an extreme risk of cancer (Li-Fraumeni syndrome, known as LFS), with a four year $1.9M commitment to fund whole-body magnetic resonance imaging (MRI) under the Medicare Benefits Schedule (MBS).

We are so pleased that 5,000 Australian cancer patients have accessed genomic technology via our Molecular Screening and Therapeutics (MoST) study.

Our team David Thomas and Mandy Ballinger has received a collaborative grant through the U.S. National Cancer Institute (NCI)'s Specialized Program of Research Excellence (SPORE).

We were thrilled to see national media coverage of the Molecular Screening & Therapeutics (MoST) study – the leading Australian program delivering molecular screening and trials matching to advanced cancer patients.

September 24th is World Cancer Research Day.

Our partners at Rare Cancers Australia have launched their new Thought Leaders podcast series, sharing a collection of candid conversations with some of the brightest minds in the Australian cancer community.

We’re proud to be collaborating with Foundation Medicine to present one of fourteen abstracts demonstrating the power of genomic profiling to advance cancer care at the 2022 ESMO – European Society for Medical Oncology, set to be held virtually and in Paris from September 9-13.

We’re proud to be the first partner in Australia to use Oncoshot’s federated data system for clinical trial insights. This partnership will enable greater access for Australian cancer patients to the latest cancer drugs via global clinical trials.

The Precision Oncology Screening Platform Enabling Clinical Trials (PrOSPeCT) will establish Australia as a medical manufacturing hub: building links from research through to the clinic; creating jobs; changing lives. A private public partnership to strengthen Australia’s position at the forefront of the cancer treatment revolution

Renowned experts discussing the future of genomic cancer medicine, developing new models for health care, data and machine learning. Join us for 4 sessions over 4 days to explore novel technologies, innovative therapies and a systems approach to managing cancer risk and providing healthcare. November Monday 22nd, Tuesday 23rd, Wednesday 24th and Thursday 25th November 2021; 5pm - 7pm AEST

Cancer Institute NSW has awarded a Translational Program Grant to an impressive team of experienced laboratory and clinical researchers in pancreas cancer, coordinated by Chief Investigator Professor David Goldstein. The team is seeking to develop better targeted treatment options for pancreatic cancer – and ultimately, improve outcomes for people affected.

View the "Demystifying the Molecular Tumour Board" Masterclass publication and webinar recordings

The first patient has been enrolled into the ‘ASPiRATION’ Study. The study is looking at the impact and value of comprehensive genomic profiling (CGP), precision medicine and personalised healthcare (PHC) in newly diagnosed metastatic, non-squamous, non-small cell lung cancer patients.

3000 patients enrolled onto the Molecular Screening and Therapeutics (MoST) program, 1000 people have enrolled in the Genetic Cancer Risk in the Young (RisC) study and 95 people have joined the Surveillance study in Multi-Organ Cancer prone syndromes (SMOC+) - great news for cancer research.

Learn how members of a Molecular Tumour Board (MTB) come together to discuss and interpret tumour molecular profiles in the clinical context, recommending therapeutic strategies for the care of patients with cancer. 4 webinars on 29th Oct, 5th, 12th and 19th Nov 2020, 4 - 5pm

The cells of the human body are constantly dividing, and each time need to copy a three billion-letter DNA code with high precision to ensure cell survival. The same is not true for cancers, researchers have discovered.

Professor David Thomas provides a glimpse of what the future of cancer research could look like.

Roche Australia, in partnership with the Australian Government announced a jointly funded a genomic profiling research project called ‘ASPiRATION’ for 1,000 Australians with newly diagnosed metastatic, non-squamous, non-small cell lung cancer.

Neglected Cancers Awareness Week is an important opportunity to call on government, corporations and the community at large to place a greater focus on less common, but high-mortality cancers.

An innovative suite of clinical trials, matching therapies with Individuals on the basis of genetic information, could one day hold the key to rare and uncommon cancers and give hope to patients who have exhausted other treatment options.